[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J, Bannon PG, McCaughan BC: Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg; 2009 Sep;138(3):619-24
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
  • OBJECTIVE: This study aimed to evaluate the perioperative and long-term outcomes associated with extrapleural pneumonectomy for patients with malignant pleural mesothelioma.
  • The prognostic factors included age, gender, side of disease, asbestos exposure, histology, positron emission tomography, date of surgery, neoadjuvant chemotherapy, completeness of cytoreduction, lymph node involvement, perioperative morbidity, adjuvant radiotherapy, and pemetrexed-based chemotherapy.
  • Six patients received neoadjuvant chemotherapy, 28 patients received adjuvant radiotherapy, and 16 patients received postoperative pemetrexed-based chemotherapy.
  • Complications included hemothorax (n = 7), atrial fibrillation (n = 6), empyema (n = 4), bronchopulmonary fistula (n = 3), right-sided heart failure (n = 2), pneumonia (n = 1), constrictive pericarditis (n = 1), acute pulmonary edema (n = 1), small bowel herniation (n = 1), and disseminated intravascular coagulopathy (n = 1).
  • Asbestos exposure, negative lymph node involvement, and receipt of adjuvant radiation or postoperative pemetrexed-based chemotherapy were associated with improved survival on both univariate and multivariate analyses.
  • CONCLUSION: The present study supports the use of extrapleural pneumonectomy-based multimodal therapy in carefully selected patients with malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cohort Studies. Female. Follow-Up Studies. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Pemetrexed. Positron-Emission Tomography. Postoperative Care. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698846.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Antman K, Hassan R, Eisner M, Ries LA, Edwards BK: Update on malignant mesothelioma. Oncology (Williston Park); 2005 Sep;19(10):1301-9; discussion 1309-10, 1313-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on malignant mesothelioma.
  • Multicystic mesotheliomas and well-differentiated papillary mesotheliomas are associated with long survival in the absence of treatment and should be excluded from clinical trials intended for the usual rapidly lethal histologic variants of the disease.
  • Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / diagnosis. Mesothelioma / epidemiology. Mesothelioma / pathology. Mesothelioma / therapy
  • [MeSH-minor] Asbestos / adverse effects. Folic Acid Antagonists / administration & dosage. Folic Acid Antagonists / therapeutic use. Heart Neoplasms / pathology. Humans. Incidence. Male. Neoplasm Staging. Peritoneal Neoplasms / pathology. Platinum Compounds / administration & dosage. Platinum Compounds / therapeutic use. Pleural Neoplasms / pathology. Prognosis. Quality of Life / psychology. Survival Analysis. Testicular Neoplasms / pathology. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285225.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; 0 / Platinum Compounds; 1332-21-4 / Asbestos
  •  go-up   go-down


3. Hillerdal G, Elmberger G: Malignant mediastinal tumor with bone formation--mesothelioma or sarcoma? J Thorac Oncol; 2007 Oct;2(10):983-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mediastinal tumor with bone formation--mesothelioma or sarcoma?
  • Mesothelioma can occur in different variants, some of which are difficult or impossible to differentiate from sarcomas.
  • The man was born in the Turkish village of Karain, where the incidence of mesothelioma is extremely high, and a sarcomatous mesothelioma was therefore diagnosed.
  • Since the tumor was pressing against the large vessels and heart, a debulking was performed, followed by Pemetrexed and Carboplatin treatment.
  • However, the tumor grew rapidly and spread to the pleura, involved the heart, and the patient succumbed.
  • This is to our knowledge the first report of a sarcomatous mesothelioma with bone formation from environmental exposure to mineral fibers.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mesothelioma / pathology. Osteogenesis. Sarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Calcification, Physiologic. Carboplatin / administration & dosage. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Pemetrexed. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / etiology. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology. Thoracoscopy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909365.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Tanida S, Kataoka H, Kubota E, Mori Y, Sasaki M, Ogasawara N, Wada T, Mizoshita T, Shimura T, Murakami K, Mizushima T, Hirata Y, Okamoto Y, Mabuchi M, Ebi M, Tanaka M, Kamiya T, Takahashi S, Joh T: Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol; 2009 Jun;14(3):266-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
  • Malignant peritoneal mesothelioma is a rare neoplasm with a rapidly fatal course.
  • The response of this disease to treatment is poor because it tends to be advanced at diagnosis and tends to have inherent resistance to chemotherapeutic treatment.
  • We describe three patients with malignant peritoneal mesothelioma who received combination chemotherapy with cisplatin and gemcitabine.
  • After a histopathological diagnosis of epithelial-type malignant peritoneal mesothelioma, all patients underwent systemic chemotherapy because of the advanced disease stage.
  • Moreover, one patient would have been at high risk of cardiac events, because of congenital heart malformation if complete surgical resection had been performed.
  • This chemotherapy achieved a partial response in two patients, but had no effect in one.
  • Combination chemotherapy with cisplatin and gemcitabine may prove to be one of the recommended treatments for patients with malignant peritoneal mesothelioma in the near future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / analysis. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):469-77, viii [15559053.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Crit Rev Diagn Imaging. 1985;24(4):293-328 [3896651.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2375-84 [10357408.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Br J Ind Med. 1964 Jan;21:20-31 [14106131.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):56-7 [12903546.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Arch Surg. 1988 Jun;123(6):763-6 [2453184.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):491-6 [12189542.001]
  • (PMID = 19593622.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Butz T, Faber L, Langer C, Körfer J, Lindner O, Tannapfel A, Müller KM, Meissner A, Plehn G, Trappe HJ, Horstkotte D, Piper C: Primary malignant pericardial mesothelioma - a rare cause of pericardial effusion and consecutive constrictive pericarditis: a case report. J Med Case Rep; 2009;3:9256

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant pericardial mesothelioma - a rare cause of pericardial effusion and consecutive constrictive pericarditis: a case report.
  • INTRODUCTION: Primary malignant pericardial mesothelioma is a very rare pericardial tumor of unknown etiology.
  • Intrapericardial fluid volume declined after repeated pericardiocentesis, but the patient progressively developed a hemodynamically relevant pericardial constriction.
  • Pericardiectomy revealed a pericardial mesothelioma.
  • Subsequently, four cycles of chemotherapy (dosage according to recently published trials) were administered.
  • CONCLUSION: Pericardial mesothelioma should be considered and managed appropriately in non-responders to pericardiocentesis, and in patients who develop constrictive pericarditis late in their clinical course.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Cardiol. 1999 Dec;15(12):1367-72 [10620743.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):245-8 [16533802.001]
  • [Cites] Lung Cancer. 2008 May;60(2):291-3 [17936406.001]
  • [Cites] Semin Diagn Pathol. 2008 Feb;25(1):47-53 [18350922.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):764-71 [18594323.001]
  • [Cites] Eur Heart J. 2004 Apr;25(7):587-610 [15120056.001]
  • [Cites] Clin Lung Cancer. 2005 Jul;7(1):40-6 [16098243.001]
  • [Cites] Heart. 2006 Sep;92(9):1289 [16908701.001]
  • [Cites] J Thorac Imaging. 2008 Feb;23(1):35-8 [18347518.001]
  • [Cites] Heart. 2004 Jan;90(1):e4 [14676267.001]
  • (PMID = 19918293.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2767155
  •  go-up   go-down


6. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C: [Malignant cardiac tumors]. Bull Cancer; 2004 Nov;91 Suppl 3:136-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant cardiac tumors].
  • Cardiac neoplasms are a rare occurrence in clinical practice.
  • The various frequencies of primary and secondary malignant tumors vary from report to report, approximately 1% in most autopsy series and 4% in cancer patient's autopsies.
  • Cardiac malignancies account for less 1% of cardiac surgery and about for 0.1% of cardiac echographic studies.
  • The presence of metastatic tumor to the heart usually indicates widespread metastases.
  • Apart from primary pericardial mesothelioma, primary cardiac tumors are high-grade sarcomas with a high metastatic potency that often becomes evident early after surgery.
  • Symptoms are non specific, occur late in the disease and affect few patients; especially secondary neoplasms of the heart take their course so fast that they cannot become symptomatic.
  • The signs of cardiac neoplasms are divided into systemic symptoms (fever, arthralgias and myalgias), cardiac symptoms (congestive heart failure, arrhythmia, chest pain) and uncommon embolisms.
  • Diagnosis is actually made easier with cardiac echography.
  • Cardiac RMI is helpful to estimate vessels and pericardium involvement.
  • Due to its poor prognosis, treatment of cardiac metastases is restricted to best supportive care.
  • For primary cardiac neoplasms, surgery must be carefully discussed because operative intervention is often followed by rapid widespread metastases that adjuvant chemotherapy cannot avoid in most cases.
  • [MeSH-major] Heart Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899620.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


7. Flynn J, Berg RW, Wong T, van Aken M, Vincent MD, Fukushima M, Koropatnick J: Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther; 2006 Jun;5(6):1423-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
  • Malignant mesothelioma is an aggressive tumor of the serosal surfaces of the lungs, heart, and abdomen.
  • Survival rates are poor and effective treatments are not available.
  • However, recent therapeutic regimens targeting thymidylate synthase (TS) in malignant mesothelioma patients have shown promise.
  • To test the potential for antisense targeting of TS mRNA in treatment of malignant mesothelioma, we assessed and compared the effects of antisense TS ODN 83 on three human malignant mesothelioma cell lines (211H, H2052, and H28) and human nonmalignant mesothelioma cells (HT29 colorectal adenocarcinoma, HeLa cervical carcinoma, and MCF7 breast tumor cell lines).
  • We report that ODN 83 applied as a single agent effectively reduced TS mRNA and protein in malignant mesothelioma cell lines.
  • Furthermore, it inhibited malignant mesothelioma growth significantly more effectively than it inhibited growth of nonmalignant mesothelioma human tumor cell lines: a difference in susceptibility was not observed in response to treatment with TS protein-targeting drugs.
  • In malignant mesothelioma cells, antisense TS both induced apoptotic cell death and reduced proliferation.
  • In nonmalignant mesothelioma cells, only reduced proliferation was observed.
  • Thus, antisense TS-mediated induction of apoptosis may be the basis for the high malignant mesothelioma sensitivity to antisense targeting of TS.
  • Further preclinical and clinical study of TS antisense oligodeoxynucleotides, alone and in combination with TS-targeting chemotherapy drugs, in mesothelioma is warranted.
  • [MeSH-major] Mesothelioma / drug therapy. Oligonucleotides, Antisense / therapeutic use. Thymidylate Synthase / metabolism
  • [MeSH-minor] Aged. Apoptosis / drug effects. Cell Proliferation. Down-Regulation. Flow Cytometry. HT29 Cells / drug effects. HT29 Cells / enzymology. HeLa Cells / drug effects. HeLa Cells / enzymology. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818500.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / RNA, Messenger; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


8. Maruyama R, Sakai M, Nakamura T, Suemitsu R, Okamoto T, Wataya H, Nishiyama K, Kamei T, Ichinose Y: Triplet chemotherapy for malignant pericardial mesothelioma: a case report. Jpn J Clin Oncol; 2006 Apr;36(4):245-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
  • Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease.
  • A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone.
  • The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion.
  • The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drainage. Drug Administration Schedule. Female. Humans. Middle Aged. Neutropenia / chemically induced. Pericardial Effusion / pathology. Remission Induction. Survivors. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533802.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


9. Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S: Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol; 2003 Jul;83(3):147-53
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
  • BACKGROUND AND OBJECTIVES: Peritoneal mesothelioma (PM) is a rare disease, with a poor prognosis.
  • We decided to prospectively evaluate the prognostic impact of aggressive surgery followed by intraperitoneal chemotherapy with local hyperthermia.
  • Fifteen (68%) patients had malignant disease, two had well-differentiated papillary mesothelioma, and two had multicystic PM.
  • Thirteen (65%) patients received preoperative chemotherapy.
  • One patient underwent the procedure twice due to locoregional progression.
  • IPHP was performed with closed abdomen technique, using a preheated polysaline perfusate (42.5 degrees C) containing cisplatin + mitomycin C or cisplatin + doxorubicin administered through a heart-lung pump for 60 or 90 min.
  • CONCLUSIONS: This therapeutic strategy proved feasible and was well tolerated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced / methods. Mesothelioma / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Drug Administration Routes. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12827682.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Vigneswaran WT, Stefanacci PR: Pericardial mesothelioma. Curr Treat Options Oncol; 2000 Oct;1(4):299-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial mesothelioma.
  • Primary pericardial mesothelioma is a rare but lethal disease.
  • In most cases the diagnosis is made at autopsy or postoperatively.
  • Clinical signs and symptoms are typically nonspecific and are similar to compromised cardiac function.
  • Surgical resection remains the main treatment modality.
  • Addition of chemotherapy or radiation has been disappointing.
  • Newer therapeutic approaches for malignant pleural mesothelioma are likely to influence the treatment of pericardial mesothelioma in the future.
  • [MeSH-major] Heart Neoplasms / therapy. Mesothelioma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Pericardium / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1995 Jul;222(1):78-86 [7618973.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1559-65 [8336195.001]
  • [Cites] J Nucl Med. 1987 Jul;28(7):1210-2 [3474368.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Am Heart J. 1992 Sep;124(3):802-3 [1514518.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):214-20 [7641017.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] Am Rev Respir Dis. 1978 Aug;118(2):419-24 [697191.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):660-1 [7993848.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Environ Res. 1980 Dec;23(2):270-81 [7472312.001]
  • [Cites] Tex Heart Inst J. 1994;21(2):170-4 [8061543.001]
  • [Cites] Chest. 1982 Apr;81(4):520-3 [7067523.001]
  • [Cites] Postgrad Med J. 1992 Feb;68(796):137-9 [1570257.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Cancer. 1970 Oct;26(4):914-9 [5506612.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1987;21(3):273-5 [3438724.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):420-6 [1934246.001]
  • (PMID = 12057155.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


11. Serke M, Loddenkemper R: [Therapeutic options in malignant pleural mesothelioma]. Pneumologie; 2005 May;59(5):337-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options in malignant pleural mesothelioma].
  • Malignant pleural mesothelioma may be treated with surgery, radiotherapy and chemotherapy.
  • In most patients, the treatment remains palliative with symptom relief and a moderate survival gain.
  • Only a minority of patients with early stage mesothelioma may be cured by a multimodal approach including radical surgery, chemotherapy, and radiotherapy.
  • We discuss the role of surgery with either radical extrapleural pleuropneumonectomy or less invasive palliative pleurectomy and decortication, and the role of radiotherapy, in which the main problem is how to deliver sufficient doses to the pleural surface, sparing radiosensitive structures such as the lung, heart, liver, and kidneys.
  • Chemotherapeutic options are discussed with 'older' mono- and combination regimens and the new promising combination cisplatinum/pemetrexed, now the 'standard regimen' for malignant pleural mesothelioma.
  • For the majority of our patients we recommend talcum pleurodesis either by medical thoracoscopy or VATS, followed by chemotherapy with platinum/pemetrexed.
  • The individual therapeutic decision will depend on tumour stage, concomitant diseases, performance status, and on the patient's preference.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902599.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 103
  •  go-up   go-down


12. McCoy MJ, Nowak AK, Lake RA: Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens; 2009 Jul;74(1):1-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
  • Whether the immune system can recognize malignant and premalignant cells and eliminate them to prevent the development of cancer is still a matter of open debate, but in our view, the balance of evidence favours this concept.
  • Nonetheless, the International Agency for Research on Cancer has now predicted that cancer will overtake heart disease as the leading cause of death worldwide by 2010, showing that this protective mechanism often fails.
  • Malignant mesothelioma has traditionally been considered a relatively non-immunogenic cancer.
  • However, mesothelioma cells do express a set of well-defined tumour antigens that have been shown to engage with the host immune system.
  • Mesothelioma should therefore be considered a target for immunotherapy.
  • A variety of anticancer immunotherapies have been investigated in mesothelioma and in other malignancies, although these have been largely ineffective when used in isolation.
  • Over recent years, there has been increasing interest in the possibility of combining immunotherapy with chemotherapy in the fight against cancer.
  • Here, we discuss the rationale behind combining these two, long considered antagonistic, treatment options in the context of malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunosuppression. Mesothelioma / therapy. Neoplasms, Mesothelial / therapy
  • [MeSH-minor] Combined Modality Therapy. Cytokines / immunology. Cytokines / metabolism. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422663.001).
  • [ISSN] 1399-0039
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cytokines
  • [Number-of-references] 93
  •  go-up   go-down


13. Papi M, Genestreti G, Tassinari D, Lorenzini P, Serra S, Ricci M, Pasquini E, Nicolini M, Pasini G, Tamburini E, Fattori PP, Ravaioli A: Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis. Tumori; 2005 May-Jun;91(3):276-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pericardial mesothelioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma. Report of two cases, review of the literature and differential diagnosis.
  • Malignant pericardial mesothelioma is an uncommon variety of a primary malignant cardio-pericardial tumor and it is a highly lethal and fortunately rare cardiac neoplasm.
  • The presentation of pericardial mesothelioma is aspecific and pathologically mesothelioma is not the most common among primary tumors of the pericardium.
  • Antemortem diagnosis is difficult and distant metastases are extremely rare.
  • Radical surgery can be used to treat localized mesothelioma.
  • The treatment for advanced primary pericardial mesothelioma is usually palliative because the tumor is resistant to radiotherapy and chemotherapy.
  • In this paper we report two cases of patients with primary mesothelioma of the pericardium without a definite history of asbestos exposure.
  • [MeSH-major] Heart Neoplasms / pathology. Mesothelioma / pathology. Pericardium / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Male. Prognosis. Survival

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206657.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


14. Molina Garrido MJ, Mora Rufete A, Rodríguez-Lescure A, Cascón Pérez JD, Ardoy F, Guillén Ponce C, Carrato Mena A: Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma. Clin Transl Oncol; 2006 Sep;8(9):694-6
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pericardial effusion as initial manifestation of primary diffuse pericardial malignant mesothelioma.
  • The case of a 61-year-old woman who presented a recurrent symptomatic pericardial effusion and a malignant cardiac tamponade six months prior to the detection of a mediastinal anterior mass is described.
  • Diffuse malignant pericardial mesothelioma was diagnosed after mediastinal mass biopsy.
  • The patient underwent further oncological evaluation followed by chemotherapy.
  • [MeSH-major] Heart Neoplasms / diagnosis. Mesothelioma / diagnosis. Pericardial Effusion / etiology. Pericardium
  • [MeSH-minor] Aged. Cardiac Tamponade / etiology. Female. Humans. Recurrence

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Clin. 1973;5(1):207-38 [4589961.001]
  • [Cites] Am Heart J. 1988 Jun;115(6):1321-2 [3376853.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):208-12 [7838044.001]
  • [Cites] J Cardiovasc Surg (Torino). 1994 Jun;35(3):261-7 [8040178.001]
  • [Cites] Cardiovasc Clin. 1976;7(3):257-69 [1000541.001]
  • [Cites] Am J Cardiol. 1979 Nov;44(6):1110-4 [495505.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):622-5 [7496510.001]
  • [Cites] Am Heart J. 1987 Mar;113(3):785-90 [3548297.001]
  • [Cites] Am Heart J. 1986 May;111(5):986-8 [3706117.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • (PMID = 17005474.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Small GR, Nicolson M, Buchan K, Broadhurst P: Pericardial malignant mesothelioma: a latent complication of radiotherapy? Eur J Cardiothorac Surg; 2008 Apr;33(4):745-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial malignant mesothelioma: a latent complication of radiotherapy?
  • Diagnosis can be challenging and often requires the use of different imaging modalities.
  • Here, we describe a case which presented with common cardiac symptoms which were shown to be the result of a rare condition.
  • Post-embolectomy she developed cardiac failure.
  • Adjuvant chemotherapy and radiotherapy were administered.
  • Cardiac MRI demonstrated thickened pericardium.
  • At cardiac catheterisation haemodynamic responses consistent with constrictive pericarditis were seen.
  • Histology revealed pericardial epithelioid malignant mesothelioma.
  • Chemotherapy with pemetrexed and carboplatin was given.
  • Radiotherapy and asbestos exposure are both associated with pericardial mesothelioma and the aetiology in this case was not clear.
  • The condition carries a poor prognosis and is invariable fatal although newer chemotherapeutic regimens have prolonged survival times.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Heart Neoplasms / etiology. Mesothelioma / etiology. Neoplasms, Radiation-Induced / etiology. Pericardium
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Pericarditis, Constrictive / etiology. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280176.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Deraco M, Kusamura S, Baratti D, Casali P, Gronchi A, Zaffaroni N: Peritoneal mesothelioma treated by cytoreductive surgery and intra peritoneal hyperthermic perfusion: Clinical and translational study. J Clin Oncol; 2004 Jul 15;22(14_suppl):9729

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal mesothelioma treated by cytoreductive surgery and intra peritoneal hyperthermic perfusion: Clinical and translational study.
  • : 9729 Background: to report the NCI of Milan experience on treating Peritoneal Mesothelioma (PM) with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP).
  • 3) development of a gene therapy approach.
  • 34 (89%) cases had malignant epithelioid disease.
  • Twenty one (53%) cases received preoperative chemotherapy.
  • The IPHP was performed with closed abdomen technique with cisplatin+mitomycin-C or cisplatin+doxorubicin through a heart-lung pump for 60 or 90 minutes at 42.5° C.
  • PM in vitro drug sensitivity was evaluated on primary cultures derived from surgical specimens.
  • We established new PM cell lines for the development of a gene therapy approach, which aimed at the inhibition of cell survival factors.
  • The assessment of sensitivity profile of 7 PM primary cultures to a panel of drugs found a variable response rate for the different compounds.
  • CONCLUSIONS: CRS+IPHP seems consistent with a potentially effective treatment for selected PM patients.
  • Further definition of drug sensitivity profile and the development gene therapies will provide a possible biological rationale for the design of new clinical treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014373.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Klaase JM, Swaanenburg JC, Schouwink H, Sosef MN, Bonfrer JM, Zoetmulder FA, Rutgers EJ, Baas P: Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers. Photochem Photobiol; 2000 Mar;71(3):351-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.
  • In five patients who were treated for malignant pleural mesothelioma (MPM) with pleuropneumonectomy and intraoperative photodynamic therapy (IPDT), impending myocardial damage was monitored using ECG, the classical biochemical markers (creatine kinase [CK], total activity; CKMB, mass; and myoglobin), and the new cardiac markers troponin I (cTnI) and troponin T (cTnT).
  • From this study in patients with MPM treated with pleuropneumonectomy and IPDT it can be concluded that measurement of cTnI and cTnT for the detection of myocardial damage is more suitable than measurement of the classical markers.
  • [MeSH-major] Heart / drug effects. Mesothelioma / drug therapy. Photochemotherapy / adverse effects. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10732455.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Troponin I; 0 / Troponin T
  •  go-up   go-down


18. Kindler HL, Herndon JE, Zhang C, Green MR, Cancer and Leukemia Group B: Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer; 2005 Jun;48(3):423-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
  • PURPOSE: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733).
  • Eligibility included a performance status of 0-2 by CALGB criteria, and no prior chemotherapy.
  • Twenty-five patients had pleural mesothelioma; two patients had peritoneal mesothelioma, and one patient had pericardial mesothelioma.
  • Three patients died of treatment-related toxicities.
  • CONCLUSION: Single-agent irinotecan in this dose and schedule has considerable toxicity in patients with malignant mesothelioma and has no anti-tumor activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893012.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Luckraz H, Rahman M, Patel N, Szafranek A, Gibbs AR, Butchart EG: Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg; 2010 Mar;37(3):552-6
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
  • BACKGROUND: Optimal management of diffuse malignant pleural mesothelioma (DMPM) remains unclear.
  • We report our 30-year surgical experience with DMPM with emphasis on surgical procedure and post-operative adjuvant therapy.
  • Consecutive patients who underwent surgical treatment were included (n=139).
  • Post-operative adjuvant therapy included either chemotherapy, radiotherapy, both or none.
  • The longest survival (median 26.0 months, IQR: 11.14-40.9 months) occurred in the pleurectomy/decortication group who received both post-operative chemotherapy and radiotherapy (n=24) (p<0.001).
  • EPP whether or not combined with adjuvant therapy provided no significant survival advantage in comparison to pleurectomy/decortication (overall median survival 10.3 months vs 10.1 months, p=0.09).
  • On univariate analysis, pleurectomy/decortication combined with chemotherapy and radiotherapy was the strongest predictor of prolonged survival (Hazard Ratio=3.6).
  • Multivariate analysis with the inclusion of histological type, surgical procedure and type of adjuvant therapy, EPP without adjuvant therapy was an independent risk-factor for decreased survival (Hazard Ratio=9.2).
  • CONCLUSIONS: In this series, cytoreductive surgery combined with post-operative adjuvant therapy provided better survival despite either advanced disease or surgically less fit patients.
  • Thus, pleurectomy/decortication may be the procedure of choice, given that neither surgical procedure (EPP or PD) is not curative.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19717307.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Yu L, Gu TX, Shi EY, Xiu ZY, Fang Q: [Diagnosis and therapy of primary malignant tumors of the heart and pericardium]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):230-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of primary malignant tumors of the heart and pericardium].
  • OBJECTIVE: To summarize and analyze the experience in diagnosis and treatment of primary malignant tumors of the heart and pericardium.
  • METHODS: The clinical data of 24 patients with malignant tumors of the heart and pericardium treated in our hospital between Jun.
  • RESULTS: All 24 patients received surgical treatment.
  • CONCLUSION: Echocardiography, CT, MRI, 3D-CT, CT of coronary artery and cardiac angiography are helpful for the diagnosis and selection of operation mode.
  • Histological examination is necessary for the final diagnosis.
  • Early diagnosis and surgical resection of the tumor as complete as possible, and combination with post-operative radiotherapy and/or chemotherapy may improve the survival of the patients.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / surgery. Mesothelioma / diagnosis. Mesothelioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myxoma / diagnosis. Myxoma / surgery. Pericardium / surgery. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615268.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Graziani I, Eliasz S, De Marco MA, Chen Y, Pass HI, De May RM, Strack PR, Miele L, Bocchetta M: Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res; 2008 Dec 1;68(23):9678-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway.
  • Malignant mesothelioma (MM) is a cancer of the lining of the lungs, heart, and intestine and is known to respond poorly to chemotherapy.
  • Here we show that malignant mesothelial cells have an elevated Notch signaling pathway compared with normal human mesothelial cells.
  • Our study also provides evidence that whereas Notch-1 is elevated in the malignant setting, Notch-2 is diminished.
  • These results provide new insight into the role of Notch in MM and suggest that Notch pathway inhibitors may be useful in the treatment of this deadly disease.
  • [MeSH-major] Mesothelioma / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Notch1 / metabolism. Receptor, Notch2 / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047145.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA, Neoplasm; 0 / NOTCH1 protein, human; 0 / NOTCH2 protein, human; 0 / RNA, Messenger; 0 / Receptor, Notch1; 0 / Receptor, Notch2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


22. Kosty MP, Herndon JE 2nd, Vogelzang NJ, Kindler HL, Green MR: High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer; 2001 Nov;34(2):289-95
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
  • Doxorubicin is the most widely studied agent for the treatment of malignant mesothelioma.
  • Higher dose doxorubicin has been successfully employed in other tumor types.
  • Dexrazoxane has been demonstrated to reduce the cardiac toxicity associated with long term, chronic use of doxorubicin.
  • Based upon phase I data generated by the Cancer and Leukemia Group B (CALGB) indicating that doxorubicin at a dose of 120 mg/m(2) when combined with dexrazoxane and GM-CSF could be safely administered, the CALGB undertook a phase II study of high-dose doxorubicin in patients with malignant mesothelioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Diseases / chemically induced. Mesothelioma / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • MedlinePlus Health Information. consumer health - Heart Diseases.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11679188.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35091; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA45564; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA77440
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


23. Clarke JM, Helft P: Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature. J Med Case Rep; 2010;4:346

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature.
  • INTRODUCTION: Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare subtype of epitheloid mesothelioma, which is usually seen in young women.
  • WDPMP is generally considered of low malignant potential, however the long-term nature of the tumor remains poorly defined.
  • CASE PRESENTATION: We describe the long-term follow-up of a 60-year-old woman of West African descent who has survived 24 years with WDPMP after receiving extensive local and systemic adjuvant chemotherapy.
  • Her clinical course has included three exploratory laparotomies with intraperitoneal and intravenous chemotherapy over two decades.
  • Her course was complicated by anthracycline-induced cardiomyopathy, for which she underwent an orthotopic heart transplant.
  • CONCLUSION: No consensus exists regarding optimal treatment strategies for WDPMP.
  • However, given the low malignant potential of the tumor, careful consideration should be made before proceeding with aggressive interventions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029480.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987960
  •  go-up   go-down


24. Roth M, Zhong J, Tamm M, Szilard J: Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases. J Biomed Biotechnol; 2009;2009:451084
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-activated protein kinases.
  • Therapy with hyperthermal chemotherapy in pleural diffuse malignant mesothelioma had limited benefits for patients.
  • In human mesothelioma and mesothelial cells heat stress (39-42 degrees C) induced the phosphorylation of two mitogen activated kinases (MAPK) Erk1/2 and p38, and increased Hsp40, and Hsp70 expression.
  • Mesothelioma cells expressed more Hsp40 and were less sensitive to heat stress compared to mesothelial cells.
  • Inhibition of Erk1/2 MAPK by PD98059 or by Erk1 siRNA down-regulated heat stress-induced Hsp40 and Hsp70 expression and reduced mesothelioma cell survival.
  • Inhibition of p38MAPK by SB203580 or siRNA reduced Hsp40, but not Hsp70, expression and also increased mesothelioma cell death.
  • Thus hyperthermia combined with suppression of p38 MAPK or Hsp40 may represent a novel approach to improve mesothelioma therapy.
  • [MeSH-major] HSP40 Heat-Shock Proteins / biosynthesis. HSP70 Heat-Shock Proteins / biosynthesis. Heat-Shock Response / physiology. Mesothelioma / metabolism. Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Occup Hyg. 2000 Dec;44(8):565-601 [11108782.001]
  • [Cites] Neurosci Lett. 2008 Feb 13;432(1):35-9 [18166272.001]
  • [Cites] Neurosci Lett. 2001 Oct 19;312(2):75-8 [11595338.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1290-5 [11710946.001]
  • [Cites] Chest. 2002 Feb;121(2):480-7 [11834661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):190-6 [12007959.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):665-72 [12014635.001]
  • [Cites] Ultrastruct Pathol. 2002 Mar-Apr;26(2):55-65 [12036093.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L859-65 [14617514.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1564-72 [11018092.001]
  • [Cites] Cell Stress Chaperones. 2003 Winter;8(4):309-16 [15115283.001]
  • [Cites] Carcinogenesis. 1994 Nov;15(11):2673-5 [7955125.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Int J Hyperthermia. 1997 Sep-Oct;13(5):507-16 [9354935.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):1005-10 [9873044.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2427-33 [15830375.001]
  • [Cites] APMIS. 2005 Jun;113(6):426-35 [15996160.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2622-9 [16081837.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):320-8 [16133113.001]
  • [Cites] Cancer Immunol Immunother. 2006 Mar;55(3):312-9 [16151807.001]
  • [Cites] Int J Hyperthermia. 2005 Dec;21(8):695-701 [16338851.001]
  • [Cites] J Cell Physiol. 2006 May;207(2):540-52 [16447244.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1561-7 [16575008.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2862-8 [16675582.001]
  • [Cites] Ann N Y Acad Sci. 2006 May;1067:343-8 [16804009.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Nov;291(5):C931-45 [16790501.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2680-91 [16782845.001]
  • [Cites] J Biochem. 2006 Dec;140(6):805-12 [17050614.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):12-20 [17354240.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1361-9 [17322281.001]
  • [Cites] Int J Hyperthermia. 2007 Aug;23(5):431-42 [17701534.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1982-8 [17545504.001]
  • [Cites] Dev Neurobiol. 2007 Nov;67(13):1815-29 [17701989.001]
  • [Cites] Int J Hyperthermia. 2008 Feb;24(1):31-9 [18214767.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):734-40 [18258197.001]
  • [Cites] Kidney Int. 2001 Sep;60(3):872-81 [11532082.001]
  • (PMID = 19551156.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP40 Heat-Shock Proteins; 0 / HSP70 Heat-Shock Proteins; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2699487
  •  go-up   go-down


25. Balli A, Lachat M, Gerber B, Baumgartner C, Glaus T: [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments]. Schweiz Arch Tierheilkd; 2003 Feb;145(2):82-7
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].
  • In a dog presenting with the clinical signs of exercise intolerance and ascites, cardiac tamponade due to suspected idiopathic pericarditis was diagnosed based on thoracic radiographs, electrocardiogram (EKG) and cardiac ultrasound.
  • After partial pericardectomy by thoracoscopy and after obtaining a histological diagnosis of mesothelioma adjuvant intracavitary chemotherapy using cisplatin was performed.
  • Already one week later the dog developed marked dyspnea due to severe pleural effusion.
  • Despite extensive treatments life span from initial presentation to euthanasia was only 5 months.
  • Necropsy revealed extensive mesothelioma metastases covering the whole pleura, epicardium and remaining pericardium.
  • Diagnostic and therapeutic aspects of (recurrent) pericardial effusion are discussed based on this case.
  • [MeSH-major] Cardiac Tamponade / veterinary. Dog Diseases / diagnosis. Heart Neoplasms / veterinary. Mesothelioma / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Euthanasia, Animal. Fatal Outcome. Male. Pericardial Effusion / etiology. Pericardial Effusion / therapy. Pericardial Effusion / veterinary. Pericardiectomy / veterinary. Pericardiocentesis / veterinary. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / therapy. Pleural Effusion, Malignant / veterinary. Recurrence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649954.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


26. Vander Salm TJ: Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg; 2000 Apr;12(2):89-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual primary tumors of the heart.
  • Primary tumors of the heart, with the exception of atrial myxomas, occur rarely; tumors metastatic to or directly invasive of the heart are far more common.
  • The last 3 may also be malignant.
  • The malignant tumors consist of various sarcomas: myxosarcoma, liposarcoma, angiosarcoma, fibrosarcoma, leiomyosarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma, reticulum cell sarcoma, neurofibrosarcoma, and malignant fibrous histiocytoma.
  • Cardiac tumors produce a large variety of symptoms through any of 4 mechanisms.
  • Bits of tumor can embolize, causing systemic deficits when the tumors are on the left side of the heart.
  • The echocardiographic appearance may also allow quite accurate prediction of the tumor type and whether it is malignant or benign.
  • Magnetic resonance imaging serves as the next most important test where the density of T1 and T2 images may allow tumor cell type identification.
  • Heart transplantation should be considered for these patients.
  • Many of the malignant tumors cannot be resected completely, either because of the extent of local spread and invasion or because of the frequent distant metastases.
  • For patients with unresectable sarcomas, radiation and chemotherapy may be used, but without great expectation of successful results.
  • [MeSH-major] Heart Neoplasms / diagnosis. Heart Neoplasms / surgery
  • [MeSH-minor] Fibroma / diagnosis. Fibroma / surgery. Hamartoma / diagnosis. Hamartoma / surgery. Heart Septum / pathology. Heart Transplantation. Hemangioma / diagnosis. Hemangioma / surgery. Humans. Hypertrophy. Mesothelioma / diagnosis. Mesothelioma / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Prognosis. Rhabdomyoma / diagnosis. Rhabdomyoma / surgery. Teratoma / diagnosis. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807431.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 69
  •  go-up   go-down


27. Sonoda S, Kumagawa Y, Inada E: A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma. J Anesth; 2010 Dec;24(6):926-9
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma.
  • A 44-year-old man underwent radical thymectomy for malignant thymoma 5 years ago.
  • He subsequently underwent right extrapleural pneumonectomy because a right pleural metastatic lesion had developed.
  • His heart rate increased to 140 bpm and then abruptly decreased to 20-30 bpm concomitant with profound systolic hypotension of 30-40 mmHg.
  • Chest X-ray showed that the heart was shifted into the right thorax.
  • Emergent re-thoracotomy was performed and the heart was found to be malrotated and herniated from an upper defect of the pericardial patch in the right thoracic cavity.
  • The heart was returned to the pericardium and the defect was covered with a pericardial patch.
  • The blood pressure and heart rate became stable.
  • The incidence of cardiac herniation after extrapleural pneumonectomy following chemotherapy for malignant pleural mesothelioma has been reported to be around 3%.
  • The risk of cardiac herniation should always be considered, especially after extrapleural pneumonectomy.
  • [MeSH-major] Heart Injuries / etiology. Hernia / etiology. Pleura / surgery. Pneumonectomy / adverse effects. Postoperative Complications / etiology. Thymectomy / adverse effects. Thymoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adult. Anesthesia, General. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cardiotonic Agents / administration & dosage. Cardiotonic Agents / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Electrocardiography. Humans. Male. Monitoring, Intraoperative. Respiration, Artificial. Supine Position. Thoracotomy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Hernia.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2007 Sep;73(9):906-8 [17939424.001]
  • [Cites] J Thorac Cardiovasc Surg. 1970 Mar;59(3):443-6 [5415089.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] J Thorac Cardiovasc Surg. 1979 Oct;78(4):623-5 [480972.001]
  • [Cites] Anaesth Intensive Care. 2005 Jun;33(3):403-9 [15973927.001]
  • [Cites] Chest. 2000 Apr;117(4):1184-5 [10767257.001]
  • [Cites] Thorax. 1974 Sep;29(5):545-52 [4428454.001]
  • [Cites] Anesth Analg. 1986 Oct;65(10):1085-8 [3752560.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Jan;19(1):89-91 [11163569.001]
  • [Cites] J Thorac Imaging. 2007 Aug;22(3):280-2 [17721344.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Apr;29(4):579-84 [16495068.001]
  • [Cites] Acta Anaesthesiol Scand. 1992 Nov;36(8):842-5 [1466225.001]
  • [Cites] Ann Surg. 1948 Nov;128(5):1012-4 [17859240.001]
  • [Cites] Anesthesiology. 1984 Apr;60(4):362-4 [6703392.001]
  • (PMID = 20737279.001).
  • [ISSN] 1438-8359
  • [Journal-full-title] Journal of anesthesia
  • [ISO-abbreviation] J Anesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cardiotonic Agents; VTD58H1Z2X / Dopamine
  •  go-up   go-down


28. Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A: Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol; 2009 May;35(5):546-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
  • AIMS: Talc pleurodesis using talc slurry via chest tube is a primary option in malignant pleural effusion, since life expectancy is short and surgical decortication is hazardous.
  • METHODS: Between March 2004 and September 2005, 51 consecutive patients with malignant pleural effusion, and clinically considered unsuitable for talc pleurodesis, received an indwelling pleural catheter (Denver PleurX).
  • There were 19 non-small cell lung cancer cases, 7 mesothelioma, and 25 with other malignancy.
  • Chemotherapy was being given to 18 patients and was not interrupted.
  • CONCLUSIONS: An indwelling pleural catheter is a safe alternative for patients with malignant pleural effusion unsuitable for talc pleurodesis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Catheters, Indwelling. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18644696.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Kanaji N, Hiyama J, Horita N, Shiota Y, Imai S: [A case of benign asbestos pleural effusion suspected on thoracoscopic examination under local anesthesia]. Nihon Kokyuki Gakkai Zasshi; 2003 Jun;41(6):382-5
MedlinePlus Health Information. consumer health - Asbestos.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In September 2001, bilateral pleural effusions were revealed on chest radiography, and continued to progress despite treatment for heart failure.
  • Antituberculous chemotherapy had no effect on the exudates.
  • Plaque was recognized on the parietal pleura; however, the serosal surfaces of the parietal and visceral pleura were smooth, and no evidence of malignancy, especially malignant mesothelioma, was noted.
  • Thoracoscopy aided in the differential diagnosis of this case.
  • [MeSH-major] Anesthesia, Local. Asbestosis / complications. Pleural Effusion / diagnosis. Thoracoscopy
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12833842.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Fujimoto N, Gemba K, Wada S, Ono K, Fujii Y, Ozaki S, Ikeda T, Taguchi K, Kunitomo T, Kishimoto T: Malignant pericardial mesothelioma with response to chemotherapy. J Thorac Oncol; 2009 Nov;4(11):1440-1
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial mesothelioma with response to chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Heart Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Echocardiography. Fatal Outcome. Female. Humans. Middle Aged. Pericardium. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861909.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement